Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Howa Yeung, Krittin J. Supapannachart, Sandy Francois, Colin H. Adler, Ragini R. Kudchadkar, David H. Lawson, Melinda L. Yushak, Afreen I. Shariff, Suephy C. Chen
Publikováno v:
JID Innovations, Vol 3, Iss 6, Pp 100232- (2023)
Relationships between cutaneous adverse effects (CAEs) and noncutaneous adverse effects (NCAEs) of melanoma immunotherapy may help identify patterns tied to distinct immunologic pathways. The objective of this study was to determine the associations
Externí odkaz:
https://doaj.org/article/23dfe9d3445c4e7cab094e4d698b1611
Publikováno v:
Mediators of Inflammation, Vol 2016 (2016)
CD4+ T cell compartments in mouse and man are composed of multiple distinct subsets each possessing unique phenotypic and functional characteristics. IL-17-producing CD4+ T cells (Th17 cells) represent a distinct subset of the CD4+ T cell lineage. Re
Externí odkaz:
https://doaj.org/article/52c4f3bb18194f1c854fee64384e13d9
Autor:
Antoni Ribas, John M. Kirkwood, Larissa A. Korde, Elad Sharon, Nageatte Ibrahim, Sama Ahsan, Scot W. Ebbinghaus, Krishna S. Gunturu, Magdalena Kovacsovics-Bankowski, Brian Gastman, Zeynep Eroglu, James Moon, Hongli Li, Douglas B. Johnson, Ragini R. Kudchadkar, Bartosz Chmielowski, Robert M. Conry, Karl D. Lewis, Pauline Funchain, Kari Kendra, Elizabeth I. Buchbinder, Justine V. Cohen, Nikhil I. Khushalani, Thach-Giao Truong, Teresa M. Petrella, Michael V. Knopp, Vernon K. Sondak, Ahmad A. Tarhini, Sapna P. Patel, Megan Othus, Kenneth F. Grossmann
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70860ad8a591df39f1504fb8bc1ae75a
https://doi.org/10.1158/2159-8290.22541236.v1
https://doi.org/10.1158/2159-8290.22541236.v1
Autor:
Tara C. Gangadhar, Giorgos C. Karakousis, Lynn M. Schuchter, Luke Walker, Hussein Tawbi, Jeffrey A. Sosman, Anna C. Pavlick, Ragini R. Kudchadkar, Naomi B. Haas, Ravi K. Amaravadi, Jianhua Zhao, Meghan Buckley, Wanleng Deng, Shujing Liu, Khalida M. Wani, Michael T. Tetzlaff, Jennifer J.D. Morrissette, Phyllis A. Gimotty, Michael A. Davies, Xiaowei Xu, Clinton Yam
Supplementary Table S1. List of antibodies used in reverse phase protein array (RPPA). A table summarizing the antibodies used for RPPA in this study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27fd0c780738d48cf0d8590c75b05981
https://doi.org/10.1158/1078-0432.22463004
https://doi.org/10.1158/1078-0432.22463004
Autor:
Tara C. Gangadhar, Giorgos C. Karakousis, Lynn M. Schuchter, Luke Walker, Hussein Tawbi, Jeffrey A. Sosman, Anna C. Pavlick, Ragini R. Kudchadkar, Naomi B. Haas, Ravi K. Amaravadi, Jianhua Zhao, Meghan Buckley, Wanleng Deng, Shujing Liu, Khalida M. Wani, Michael T. Tetzlaff, Jennifer J.D. Morrissette, Phyllis A. Gimotty, Michael A. Davies, Xiaowei Xu, Clinton Yam
Legends for Supplementary Tables S1-S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1cc81db29dd27dc3e539d09e9b8391
https://doi.org/10.1158/1078-0432.22463007
https://doi.org/10.1158/1078-0432.22463007
Autor:
Tara C. Gangadhar, Giorgos C. Karakousis, Lynn M. Schuchter, Luke Walker, Hussein Tawbi, Jeffrey A. Sosman, Anna C. Pavlick, Ragini R. Kudchadkar, Naomi B. Haas, Ravi K. Amaravadi, Jianhua Zhao, Meghan Buckley, Wanleng Deng, Shujing Liu, Khalida M. Wani, Michael T. Tetzlaff, Jennifer J.D. Morrissette, Phyllis A. Gimotty, Michael A. Davies, Xiaowei Xu, Clinton Yam
Purpose: The objectives of the study were to evaluate the safety of daily oral PX-866 in combination with twice daily vemurafenib and to identify potential predictive biomarkers for this novel combination.Experimental Design: We conducted a phase I,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f0cf96a2a608afc886ba7d079af892
https://doi.org/10.1158/1078-0432.c.6525279.v1
https://doi.org/10.1158/1078-0432.c.6525279.v1
Autor:
Michael A. Postow, Peter A. Forsyth, Hussein Abdul-Hassan Tawbi, Igor Puzanov, Ahmad A. Tarhini, Jasmine I. Rizzo, Alain Algazi, F. Stephen Hodi, Omid Hamid, Anna C. Pavlick, Sekwon Jang, Ragini R. Kudchadkar, Christopher D. Lao, Karl D. Lewis, David A. Reardon, Nikhil I. Khushalani, Stergios J. Moschos, Kim Margolin, John A. Glaspy, Reena Thomas, Anne Sumbul, Michael B. Atkins, M. S. Ernstoff
Publikováno v:
Neuro-Oncology
Neuro Oncol
Neuro-oncology, vol 23, iss 11
Neuro Oncol
Neuro-oncology, vol 23, iss 11
Background In patients with melanoma and asymptomatic brain metastases (MBM), nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present the first report for patients who were symptomatic and/or required corticosteroids
Autor:
Marvi Tariq, Constance Harrell Shreckengost, Chao Zhang, Michael C. Lowe, Clara R. Farley, Ragini R. Kudchadkar, Keith A. Delman
Publikováno v:
Annals of Surgical Oncology. 28:6140-6151
The impact of obesity on early-stage melanoma is poorly understood. We examined the impact of overweight and obesity on clinical outcomes in locoregional melanoma. Adults who underwent surgery at Emory University Healthcare between 2010 and 2017 for
Autor:
Chrystal M. Paulos, Jessica M Keilson, Hannah M. Knochelmann, Michael C. Lowe, Ragini R. Kudchadkar
Publikováno v:
J Surg Oncol
While surgical resection, local and cytotoxic therapies have long formed the basis of cancer care, immunotherapy now plays a key role in supplementing and even replacing these agents in the first line. Here we review the early success of programmed c
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb